DNA Biomed Solns (DNA) — Cash Flow-to-Debt Ratio
DNA Biomed Solns (DNA) has a Cash Flow-to-Debt Ratio of -0.16x as of June 2023, meaning its operating cash flow of ILA-265.00K could theoretically repay 0% of its total liabilities (ILA1.67 Million) in one year. See how much free cash does DNA Biomed Solns generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DNA Biomed Solns Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for DNA Biomed Solns across 12 annual periods. Also explore DNA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for DNA Biomed Solns (2013–2024)
Year-by-year debt coverage analysis for DNA Biomed Solns. For market capitalisation and broader financial context, see market cap of DNA Biomed Solns.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | ILA1.61 Million | ILA2.81 Million | ▲ +224.1% |
| 2023 | -0.46x | ILA-678.00K | ILA1.47 Million | ▼ -145.0% |
| 2022 | -0.19x | ILA-354.00K | ILA1.88 Million | ▲ +97.7% |
| 2021 | -8.12x | ILA-2.33 Million | ILA287.00K | ▼ -13914.7% |
| 2020 | -0.06x | ILA-611.00K | ILA10.54 Million | ▲ +63.9% |
| 2019 | -0.16x | ILA-1.37 Million | ILA8.55 Million | ▼ -52.9% |
| 2018 | -0.11x | ILA-1.66 Million | ILA15.81 Million | ▲ +50.4% |
| 2017 | -0.21x | ILA-1.91 Million | ILA8.99 Million | ▼ -80.2% |
| 2016 | -0.12x | ILA-14.30 Million | ILA121.59 Million | ▲ +72.7% |
| 2015 | -0.43x | ILA-15.57 Million | ILA36.10 Million | ▼ -8.6% |
| 2014 | -0.40x | ILA-10.99 Million | ILA27.68 Million | ▲ +29.5% |
| 2013 | -0.56x | ILA-5.17 Million | ILA9.19 Million | — |